Health Canada approves updated Novavax vaccine to protect against COVID-19 – CBC

Vaccine targets XBB.1.5 variant circulating globally earlier this year

Dec 05, 2023

Health Canada has authorized an adapted vaccine from Novavax to prevent COVID-19 in people age 12 and older.

Novavax’s product — Nuvaxovid XBB.1.5 Omicron subvariant COVID-19 vaccine — uses a more traditional approach to defend the body against severe infection, hospitalization and death.

It is also authorized as a booster for those 18 and older, according to Health Canada’s webpage.

Novavax said it expects to have doses available across the country.

Novavax’s first vaccine to protect against COVID-19, known as Nuvaxovid, was authorized for use in Canadians 18 and over by Health Canada in February 2022.

Pfizer-BioNTech and Moderna’s mRNA vaccines have also been updated to target XBB.1.5 and are approved for use in Canada, including in kids under 12.

Read more: https://www.cbc.ca/news/health/novavax-nuvaxovid-covid-19-vaccine-1.7049757